Chevy Chase, MD – According to filings with the U.S. Securities and Exchange Commission, CiVi Biopharma is raising $27,456,172.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Shal Jacobovitz played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About CiVi Biopharma

CiVi Biopharma Holding Corp. is a clinical-stage research and development biotechnology company whose mission is to create novel cardiovascular and metabolic therapies that have meaningful value to patients. The company has multiple assets in various stages of development. Through its wholly-owned subsidiary, Eicos Sciences, Inc., CiVi Biopharma is advancing intravenous iloprost in Phase 3 clinical trials for the treatment of Systemic Sclerosis. In addition, CiVi is in Phase 2 clinical development of CiVi 007, a next-generation PCSK9, for the treatment and prevention of cardiovascular disease and is in the early-stage development of CiVi 020, a highly selective and potent PPAR agonist, for a variety of rare diseases. Founded in 2017, by Chief Scientific Officer, Henrik Oerum, and led by Chief Executive Officer, Shal Jacobovitz, the company is headquartered in Chevy Chase, MD.

To learn more about CiVi Biopharma, visit http://www.civibiopharma.com/

Contact:
Shal Jacobovitz, Chief Executive Officer
301-968-2390
https://www.linkedin.com/in/shal-jacobovitz-824a085/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved